An Exploratory Investigation of the Use of Drive App to Measure Sleep Parameters in Users of CPAP Therapy

Obstructive Sleep Apnea Clinical Trial

Official title:

An Exploratory Investigation of the Use of Drive App to Measure Sleep Parameters in Users of CPAP Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04500327
• Other study ID #: DHT-20-04-01
• Status: Recruiting
• Phase: N/A
• Start date: June 25, 2020
• Est. completion date: June 2021

Study information

• Verified date: July 2020
• Source: ResMed
• Contact: Neha Banodkar
• Phone: (02) 8884 2656
• Email: neha.banodkar[@]resmed.com.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the usability and suitability of the Drive app (app under test) to measure sleep parameters during CPAP use.

This is a prospective, non-randomized, single arm exploratory study without blinding.

Current users of CPAP therapy will be recruited for this study and will be provided with a smartphone (app under test installed) and a non-contact motion sensor in their home environment. These devices will measure sleep metrics such as sleep stages and breathing metrics that may be associated with sleep disordered breathing. Usage and setup instructions will be provided for the study.

Participants will contribute up to 7 overnight recordings in the home environment and will complete daily questionnaires detailing their experience.

The study may be completed in two distinct phases, with an analysis performed after each phase. Each phase is expected to last up to six weeks with the overall study duration taking up to 12 months.

Description:

The study may be completed in two distinct phases, with an analysis performed after each phase.

Phase 1 (Exploratory): A minimum of 10 and up to 12 participants will be recruited to identify any issues in using the app when used in conjunction with CPAP therapy (e.g. missed signals, inappropriate classification of breathing signals).

Phase 2 (Iterative Updates): Where changes to the algorithm or user interface are required, an additional 30 and up to 35 participants may be tested to provide design confidence. Conversely, if substantial issues are experienced and the time and effort required to address the issues is sufficiently large, the study may terminate before completion of phase 2.

Each phase is expected to last up to six weeks with the overall study duration taking up to 12 months.

Participants will be required to visit ResMed twice. The first visit will involve briefing of the study, consent form signatures, briefing on trial equipment and setup/usage instructions. The second (last) visit will involve going through the daily questionnaires with participants, collecting trial equipment and providing reimbursement for the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: June 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants willing to give written informed consent

• Participants who can read and comprehend English

• Participants who = 18 years of age

• Participants established on CPAP therapy for the treatment of OSA for = 6 months

• Participants who are able to set up the trial devices (ideally on a bedside table) with the following criteria:

• Trial devices must be 10 cm higher than the mattress

• Approx. 40 cm from the person's chest in bed

• Participants that have access to WI-FI in their home environment

• Participants who can trial the device for up to 7 nights

• *Participants who have been compliant (average of =4 hours of usage) to therapy for up to 7 nights of use

• Note: the most recent consecutive 7 nights within the last 30 days

Exclusion Criteria:

• Participants using Bilevel flow generators

• Participants who are or may be pregnant, breastfeeding or within 6 weeks postpartum (which are known to cause significant sleep disruption)

• Participants with a preexisting lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer; fibrosis of the lungs; recent (< 2years) case of pneumonia or lung infection; lung injury.

• Participants believed to be unsuitable for inclusion by the researcher

• *Participants using one of the following devices or Apps during the research period, or any other sleep tracking devices: SPlus, SleepScore app, SleepScore Max.

• Note: If the participant uses the devices or apps above and they agree to delete/not use them during study period, they can be included in the study.

Related Conditions & MeSH terms

• Obstructive Sleep Apnea
• Sleep Apnea, Obstructive

Intervention

Other:
• Drive app
The Drive app will be used to monitor sleep metrics for users of CPAP therapy.

Device:
• Non contact motion sensor
The non contact motion sensor will be used as a reference to the Drive app i.e. Drive app overnight recordings will be compared to the non contact motion sensor overnight recordings.

Locations

Country	Name	City	State
Australia	ResSleep	Sydney	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
ResMed

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identify any failures when using the Drive app for users of CPAP therapy	This will be based on: Subjective data from daily questionnaires sent out to participants; Comparison between Drive app data with the non contact motion sensor and CPAP data; The questionnaire has yes/no questions and a likert scale (from 0-10) that participants fill in to indicate how representative each nights sleep hypnogram is. For e.g. if the participant was awake between 12am-1am but the app reports that the subject is in deep sleep, this will be captured in the questionnaire.; Metrics including accuracy, correlation, total cohens kappa will be used for each signal recorded by the app which will be used to compare to the data from the reference devices.	12 months (includes Phase 1 and Phase 2 and interim data analysis)
Secondary	Evaluate usability of the Drive app	This will be based on subjective data from daily questionnaires sent out to participants.; This data will be captured from comments by the participants in the daily questionnaires.	12 months (includes Phase 1 and Phase 2 and interim data analysis)
Secondary	Compare subjective sleep quality data with data generated on the app.	This will be based on subjective data from daily questionnaires sent out to participants.; The questionnaire has yes/no questions and a likert scale (from 0-10) that participants fill in to indicate how representative each nights sleep hypnogram is. For e.g. if the participant was awake between 12am-1am but the app reports that the subject is in deep sleep, this will be captured in the questionnaire.	12 months (includes Phase 1 and Phase 2 and interim data analysis)
Secondary	Compare the Drive app sleep data to data from the reference devices.	Analyses will be performed to compare the Drive app data with the non contact motion sensor and CPAP device.; Metrics including accuracy, correlation, total cohens kappa will be used for each signal recorded by the app which will be used to compare to the data from the reference devices.	12 months (includes Phase 1 and Phase 2 and interim data analysis)